Clinical TrialMay 22, 2026, 09:02 AM
Oncolytics to Present Positive Pelareorep Trial Data at ASCO 2026
AI Summary
Oncolytics Biotech announced it will present positive translational data from its GOBLET and AWARE-1 clinical trials at the 2026 ASCO Annual Meeting. The data demonstrates that pelareorep, an investigational immunotherapy, expands pre-existing tumor-reactive immune cells and induces a multi-step immune activation process, including the expansion of mutant KRAS-specific T-cell clones. These findings correlate with tumor volume reductions in pancreatic cancer and support pelareorep's mechanism of action in difficult-to-treat cancers.
Key Highlights
- Oncolytics to present translational data from GOBLET and AWARE-1 trials at ASCO 2026.
- Pelareorep expands pre-existing tumor-reactive immune cells, not introducing new antigens.
- Induces antiviral immune response and activates tumor-specific T cells, leading to tumor regression.
- In pancreatic cancer, T-cell expansion correlated with tumor volume reductions.
- Confirmed expansion of mutant KRAS-specific T-cell clones.
- In breast cancer, increased antiviral and immune gene expression, and tertiary lymphoid structure formation.
Price Impact
More from ONCY